Table 1 Patients’ demographics, tumor characteristic, prognostic factor, and clinical outcomes

Adem et al. [1]

Single institution study

Fibrosarcoma, angiosarcoma, pleomorphic sarcoma > myxofibrosarcoma > leiomyosarcoma > hemangiopericytoma, osteosarcoma, excluding radiation-induced sarcoma and phyllodes tumor

1 adjuvant chemotherapy; 4 adjuvant radiotherapy

Tumor size > 5 cm

Overall survival 66% Sarcoma-specific survival 70% at 5 years

Bousquet et al. [3]

Multicenter study

Angiosarcoma (including radiation-induced sarcoma) >> malignant histiocytofibroma > fibrosarcoma > liposarcoma > leiomyosarcoma > osteogenic sarcoma, excluding phyllodes tumor

11 neoadjuvant chemotherapy; 19 adjuvant chemotherapy; 50 adjuvant radiotherapy

Residual tumor after treatment, cellular pleomorphism, angiosarcoma

Overall survival 44% at 5 years

Fields et al. [14]

Single institution study

Leiomyosarcoma = malignant fibrous histiocytoma = fibrosarcoma > carcinosarcoma = angiosarcoma = epithelioid cell sarcoma = rhabdomyosarcoma, excluding radiation-induced sarcoma and phyllodes tumor

5 adjuvant chemotherapy; 9 adjuvant radiotherapy

Tumor size > 5 cm

Overall survival 67% at 5 years

Pencavel et al. [4]

Single institution study

Angiosarcoma (including radiation-induced sarcoma) > phyllodes tumor > dermatofibrosarcoma protuberans > Leiomyosarcoma > fibrosarcoma = pleomorphic > malignant fibrous histiocytoma = synovial

No adjuvant chemotherapy; 24 neoadjuvant radiotherapy

Radiation-induced sarcoma

Sarcoma-specific survival 93% at 2 years, 78% at 5 years

Toesca et al. [2]

Single institution study

Angiosarcoma (including radiation-induced sarcoma) >> stromal sarcoma excluding phyllodes and dermatofibrosarcoma

5 adjuvant chemotherapy; 6 adjuvant radiotherapy

Secondary sarcoma (radiation-induced sarcoma, chronic lymphedema)

Sarcoma-specific survival 56.6% at 5 years